Literature DB >> 10625092

Pseudomonas aeruginosa from patients with cystic fibrosis affects function of pulmonary surfactant.

G Lema1, D Dryja, I Vargas, G Enhorning.   

Abstract

Patients with cystic fibrosis are severely affected by an infection with Pseudomonas aeruginosa, a microbe known to synthesize phospholipase C. This study was designed to determine whether that enzyme would affect the function of pulmonary surfactant phospholipids. Mucoid and nonmucoid strains of P. aeruginosa, freshly obtained from patients with cystic fibrosis, were cultured for 12 h on agar plates. The bacteria were suspended in saline solution and then pelleted by centrifugation. The supernatant was used to dilute the surfactant preparation, calf lung surfactant extract, from 35 to 2 mg/mL. Surfactant function, before and after incubation, was examined with a capillary surfactometer, an instrument specifically developed for an evaluation of the ability of surfactant to maintain patency of a narrow glass tube, simulating a terminal conducting airway. Phospholipid hydrolysis was also evaluated biochemically by determining the total content of phospholipids in surfactant before and after incubation. In five experiments, the lipids were separated with thin-layer chromatography, and the phosphorus content was determined in the diacylphosphatidylcholine band before and after incubation for 6, 24, and 48 h. Capillary openness and phospholipid concentration decreased as enzyme concentration and time of incubation increased (p<0.0001). Linear regression showed a significant correlation between time of capillary openness and phospholipid concentration (r = 0.957; p<0.0001). Calf lung surfactant extract hydrolysis was catalyzed by extracts of the bacteria, particularly the nonmucoid, analogous to the catalysis observed with phospholipase C. Surfactant hydrolysis catalyzed by enzymes from P. aeruginosa might severely affect surfactant function provided enzyme concentration is high and time of incubation is long.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10625092     DOI: 10.1203/00006450-200001000-00021

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  5 in total

1.  Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.

Authors:  Matthew J Wargo; Maegan J Gross; Sathish Rajamani; Jenna L Allard; Lennart K A Lundblad; Gilman B Allen; Michael L Vasil; Laurie W Leclair; Deborah A Hogan
Journal:  Am J Respir Crit Care Med       Date:  2011-05-11       Impact factor: 21.405

2.  The Pseudomonas aeruginosa flagellum confers resistance to pulmonary surfactant protein-A by impacting the production of exoproteases through quorum-sensing.

Authors:  Zhizhou Kuang; Yonghua Hao; Sunghei Hwang; Shiping Zhang; Eunice Kim; Henry T Akinbi; Michael J Schurr; Randall T Irvin; Daniel J Hassett; Gee W Lau
Journal:  Mol Microbiol       Date:  2011-01-06       Impact factor: 3.501

Review 3.  Ethanolamine utilization in bacterial pathogens: roles and regulation.

Authors:  Danielle A Garsin
Journal:  Nat Rev Microbiol       Date:  2010-04       Impact factor: 60.633

4.  GbdR regulates Pseudomonas aeruginosa plcH and pchP transcription in response to choline catabolites.

Authors:  Matthew J Wargo; Tiffany C Ho; Maegan J Gross; Laurie A Whittaker; Deborah A Hogan
Journal:  Infect Immun       Date:  2008-12-22       Impact factor: 3.441

5.  The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats.

Authors:  Xiwen Gao; Yi Huang; Yipin Han; Chun-Xue Bai; Guifang Wang
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.